NEW YORK, February 20, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including Arrowhead (NASDAQ: ARWR), Bioanalytical Systems (NASDAQ: BASI), Cleveland BioLabs (NASDAQ: CBLI), Dyax (NASDAQ: DYAX), and Exact Sciences (NASDAQ: EXAS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ARWR Research Report: ( http://get.analystsreview.com/pdf/?c=Arrowhead&d=20-Feb-2015&s=ARWR ),

BASI Research Report: ( http://get.analystsreview.com/pdf/?c=Bioanalytical%20Systems&d=20-Feb-2015&s=BASI ),

CBLI Research Report: ( http://get.analystsreview.com/pdf/?c=Cleveland%20BioLabs&d=20-Feb-2015&s=CBLI ),

DYAX Research Report: ( http://get.analystsreview.com/pdf/?c=Dyax&d=20-Feb-2015&s=DYAX ),

EXAS Research Report: ( http://get.analystsreview.com/pdf/?c=Exact%20Sciences&d=20-Feb-2015&s=EXAS ).

============

--

Analyst Update: Quarterly Earnings, Appointments, Issuance of Patents, and Upcoming Conference Calls

Reviewed by: Rohit Tuli, CFA(R)

The US stock markets closed on a mixed note on Thursday. The Nasdaq rose for a seventh straight session boosted by a rally of 8.5% in the Priceline Group shares. The Dow and the S&P 500 on the other hand eased following declines in energy shares and a disappointing outlook from Wal-Mart. Uncertainty over prospects of a debt deal with Greece added to investor caution. Dow Jones Industrial Average closed down 44.08 points, or 0.24%, at 17,985.77; S&P 500 closed down 2.23 points, or 0.11%, at 2,097.45; while the Nasdaq closed up 18.34 points, or 0.37%, at 4,924.70. Europe's stock rally lost steam on Thursday, with a benchmark index retreating from a seven-year high, after Germany rejected a new proposal from Athens for an extension of its bailout programme. The German finance ministry described the Greek proposal as "not a substantial solution" because it failed to fulfill the conditions of an EU/IMF bailout programme. In Asia, the Nikkei rose to a 15-year high following better-than-expected export data, while trade in the rest of Asia was quiet with several markets closed for Lunar New Year.

Arrowhead Research Corporation (Arrowhead) recently announced its Q1 FY 2015 financial results. Revenue for the quarter nearly quadrupled to $170,750 compared to $43,750 in the comparable quarter last year. During the quarter, the Company also expanded its management team with the appointment of Susan Boynton as Vice President, Regulatory Affairs and Patrick O'Brien as General Counsel.

Bioanalytical Systems, Inc. (Bioanalytical Systems) announced the appointment of Srini Jayaraman, Ph.D. as Principal Investigator Discovery, and Braden M. Kemmerling D.V.M. as Attending Veterinarian Preclinical Services to the scientific team. Dr. Jayaraman will lead the Company's discovery efforts and report to James Bourdage, Vice President of Bioanalytical Operations; while Dr. Kemmerling will be responsible for heading up the expanded veterinary department, including surgical support, reporting to Philip A. Downing, Senior Director, Preclinical Services.

Cleveland BioLabs, Inc. (Cleveland BioLabs) has expanded its Entolimod Patent Portfolio with the new composition of Matter Patents. With the addition of these patents, the Company now holds more than 10 issued or allowed U.S. patents covering compositions of matter and methods of use claims relating to entolimod's biodefense indication, as well as chemotherapy adjuvant and reperfusion injury indications.

Dyax Corp. (Dyax) has scheduled to release it Q4 and full year 2014 financial results on Tuesday, February 24, 2015, before market opens. The release will be followed by a conference call. As per Zacks investment research, the Company is expected to report net loss per share of $0.04 and $0.12 for Q4 2014 and full-year 2014, respectively.

EXACT Sciences Corporation (Exact Sciences), a molecular diagnostics company focused on colorectal cancer, has scheduled to host a conference call to discuss its fourth-quarter 2014 financial results on February 24, 2015, at 10:00 a.m. ET (9:00 a.m. CT). As per Zacks investment research, the Company is expected to report net loss per share of $0.39 for Q4 2014 and $1.25 for full-year 2014, respectively.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review